Most commercial plans will cover Zepbound, but almost all of them make you clear a prior authorization first. The usual bar: a BMI of 30 or higher, or 27 with a weight-related condition, plus proof you have tried diet and exercise. There is also big 2026 news. CVS Caremark dropped Zepbound in July 2025, then reversed course and is bringing it back as a preferred option on October 1, 2026. Here is exactly what your insurer wants to see, how the sleep apnea pathway can unlock coverage, and how to win an appeal if you are denied.
If your plan will not budge, you are not out of options. Many readers who get denied switch to compounded tirzepatide through a licensed telehealth provider, the same active ingredient as Zepbound, for a flat monthly cash price. The full coverage playbook is below.
🔑 Key Takeaways
- Coverage is common but conditional. Many commercial plans cover Zepbound, but plan sponsors (your employer) can opt out of GLP-1 weight-loss coverage entirely, so a yes from one plan means nothing for another.
- Prior authorization is nearly universal. Expect to document a BMI of 30 or higher (or 27 with a comorbidity) and a history of diet and exercise.
- CVS Caremark reversed itself. After excluding Zepbound in July 2025, CVS announced it returns as a co-preferred option on October 1, 2026.
- Sleep apnea can be a side door. Zepbound is FDA approved for moderate-to-severe obstructive sleep apnea, and that indication is not blocked by weight-loss exclusions.
- Medicare will not cover it for weight loss, but the new GLP-1 Bridge offers a $50 monthly copay on the Zepbound KwikPen for eligible Part D members.
Telehealth Comparison Table
If your insurer denies Zepbound and an appeal stalls, these are the two telehealth providers our readers use most for compounded tirzepatide, the same molecule, at a flat cash price.
Is Zepbound covered by insurance in 2026?
Sometimes, and it depends on two things: your pharmacy benefit manager and your employer. Many commercial and employer plans do cover Zepbound for weight management, but coverage for obesity drugs is optional. A plan sponsor can decide not to cover GLP-1 medications for weight loss at all, even when the standard formulary lists the drug. That is why your coworker can pay $25 while you get a flat denial on the same insurance brand.
So the honest answer is: check your specific plan, not a general chart. Call the member number on your card and ask two questions. Is Zepbound on my formulary, and is it covered for weight management or only for sleep apnea? The second question matters more than most people realize, as you will see below.
The CVS Caremark reversal: dropped in 2025, back October 2026
This is the biggest coverage story of the year. In a move that frustrated millions of patients, CVS Caremark, the largest pharmacy benefit manager in the country, removed Zepbound from its standard commercial formulary on July 1, 2025, and made Wegovy the preferred weight-loss option. Then, after sustained patient backlash, CVS reversed course.
| Date | What changed at CVS Caremark |
|---|---|
| July 1, 2025 | Zepbound removed from the standard commercial formulary; Wegovy became the preferred GLP-1 for weight loss |
| June 1, 2026 | CVS removes the new-to-market block on Lilly's oral pill Foundayo (orforglipron), where approved |
| October 1, 2026 | Zepbound returns to the standard commercial template as a co-preferred option |
One caveat that the headlines skip: the standard template covers roughly 25 to 30 million members, but plan sponsors can still opt out of GLP-1 weight-loss coverage. If your employer chose to exclude these drugs, the October change may not reach you. Confirm with your own plan before you celebrate.
Zepbound prior authorization criteria
Nearly every plan that covers Zepbound requires prior authorization, a form your prescriber submits to prove you meet medical criteria. The exact bar varies by insurer, but UnitedHealthcare's published commercial policy is a good template for what most plans want:
- A BMI of 30 kg/m2 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, or obstructive sleep apnea.
- Documentation that you are enrolled in or have tried a reduced-calorie diet and increased physical activity.
- The prescription is for an FDA-approved use.
Initial approval is usually granted for 6 months. The cleaner your prescriber makes the paperwork, with your BMI, your conditions, and your prior weight-loss attempts all documented, the more likely it sails through on the first try.
Step therapy: what you may have to try first
Some plans add step therapy, meaning you must try and fail a preferred drug before they approve Zepbound. Commonly required first steps include Wegovy, Saxenda, Qsymia, or phentermine. If you have already tried one of these and it did not work or caused side effects, your prescriber can file that history to skip the step. Do not start over from scratch if you have a documented past failure. Make sure it is in your record.
Reauthorization: the weight loss you need to keep coverage
Getting approved is only round one. To renew coverage after the first 6 months, most plans require proof that the drug is working. PBM policies typically want documented continued weight loss to reauthorize. If you have lost weight and kept it off, renewal is routine. If your weight has stalled, talk to your prescriber before the authorization lapses so there is a plan in place.
The sleep apnea backdoor that unlocks coverage
Here is the angle most coverage guides miss. In December 2024, the FDA approved Zepbound as the first medication for moderate-to-severe obstructive sleep apnea in adults with obesity. That is a separate, non-weight-loss indication. When a plan excludes weight-loss drugs but you genuinely have sleep apnea, the OSA pathway can get Zepbound covered anyway.
The criteria are stricter. UnitedHealthcare's OSA policy for Zepbound, for example, requires:
- A diagnosis of moderate-to-severe OSA, age 18 or older, and a BMI of 30 or higher.
- A sleep study showing an AHI, REI, or RDI greater than 15 events per hour.
- At least one prior unsuccessful attempt at diet and weight loss.
- Continued OSA symptoms despite using CPAP or another PAP device (at least 4 hours a night, at least 70 percent of nights), or documentation that you cannot tolerate PAP.
- No type 2 diabetes diagnosis (HbA1c at or below 6.5 percent).
- A prescription written by or with a sleep specialist.
Approval runs 6 months, and renewal requires a documented drop in your AHI, RDI, or REI. If you have untreated or poorly controlled sleep apnea, raise this pathway with your doctor. Read more about the data behind it in our guide to tirzepatide for sleep apnea.
Does Medicare cover Zepbound?
Not for weight loss. By federal law, Medicare Part D cannot pay for drugs used for weight loss, so a Zepbound prescription written purely for obesity is excluded. Part D plans can, however, cover Zepbound for the sleep apnea indication, since that is not a weight-loss use.
There is also a new path. CMS created a temporary Medicare GLP-1 Bridge that covers obesity GLP-1s, including the Zepbound KwikPen, at a $50 monthly copay for eligible Part D beneficiaries, beginning July 1, 2026. Lilly's own access page confirms the $50 KwikPen price for eligible Medicare patients through this program. Reporting on the program's exact end date has varied, with CMS materials pointing to an extension through December 31, 2027, so confirm the current window and your eligibility before relying on it. The $50 copay generally does not count toward your Part D deductible or out-of-pocket maximum.
How to appeal a Zepbound denial
A denial is not the end. It is the start of a process insurers expect you to use, and many approvals come on appeal. Work through it in order:
- Get the exact denial reason in writing. The three common ones are non-formulary, step therapy not met, and not medically necessary. Your strategy depends on which.
- Have your prescriber refile the prior authorization with complete documentation: BMI, weight-related conditions, prior diet and drug attempts, and lab values.
- Request a formulary exception if the drug is non-formulary or excluded. Your doctor states why covered alternatives are not appropriate for you.
- File an internal appeal if the exception is denied. This is a formal review by the plan.
- Escalate to an external independent review if the internal appeal fails. An outside reviewer, not your insurer, makes the call.
- Pivot to the OSA pathway if you qualify and the weight-loss route is a hard exclusion. It is sometimes the faster yes.
What Zepbound costs if it is not covered
If coverage simply will not happen, know your cash numbers so you can choose the cheapest real route. The branded pen lists for over $1,000 a month, but Lilly's self-pay options and compounded alternatives are far lower:
- LillyDirect self-pay vials: $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg and above, as of the December 2025 price cut.
- Commercial savings card: as little as $25 a month if you have commercial insurance that covers the drug, or as low as $499 if your commercial plan does not cover it.
- Compounded tirzepatide via telehealth: often $150 to $400 a month for the same active ingredient, compared in the table above.
For the full price breakdown, see our guide to what Zepbound costs and cheaper options, how to buy Zepbound online, and real tirzepatide reviews from patients.
Frequently Asked Questions
The bottom line
Zepbound coverage in 2026 comes down to three moves: confirm whether your specific plan covers obesity drugs at all, get a clean prior authorization filed with your BMI and conditions documented, and use the sleep apnea pathway if weight loss is excluded but you qualify. If you are on Medicare, watch the GLP-1 Bridge. And if every door closes, LillyDirect vials and compounded tirzepatide keep the same medicine within reach. Match your situation to the right pathway and you will not leave coverage on the table.
References
- CVS Health. CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications. cvshealth.com.
- CNBC. CVS to restore Zepbound coverage and add Eli Lilly's Foundayo. May 28, 2026. cnbc.com.
- Massachusetts GIC. CVS Caremark decides to remove Zepbound from formulary (effective July 1, 2025). mass.gov.
- UnitedHealthcare. Commercial Prior Authorization Notification, Weight Loss agents (BMI criteria, 6-month authorization). uhcprovider.com.
- UnitedHealthcare. Zepbound (non-formulary) OSA Prior Authorization policy. uhcprovider.com.
- U.S. FDA. FDA Approves First Medication for Obstructive Sleep Apnea (Zepbound). December 2024. fda.gov.
- KFF. What Medicare's Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries. kff.org.
- KFF. What to Know About the BALANCE Model and the Medicare GLP-1 Bridge. kff.org.
- Eli Lilly. Zepbound Access and Coverage ($50 KwikPen via GLP-1 Bridge; prior authorization). zepbound.lilly.com.
- The Boston Globe. CVS restores Zepbound coverage after patient backlash. May 29, 2026. bostonglobe.com.
- HHS ASPE. Medicare Coverage of Anti-Obesity Medications (statutory background). aspe.hhs.gov.
- U.S. FDA. Zepbound (tirzepatide) Prescribing Information (indications, dosing). accessdata.fda.gov.
